+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antispasmodics Drugs Market Research Report by Drug type, Route of administration, End-User, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5336390
  • Report
  • April 2022
  • Region: Global
  • 199 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • ACTIZA PHARMACEUTICAL
  • Allergan, Inc.
  • Aurobindo Pharma Limited
  • Fresenius Kabi AG
  • Lannett Company, Inc.
  • Mylan N.V.
The Global Antispasmodics Drugs Market size was estimated at USD 11.60 billion in 2021, USD 12.54 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.26% to reach USD 18.69 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Antispasmodics Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug type, the market was studied across Dicyclomine hydrochloride, Hyoscyamine, and Loperamide hydrochloride.
  • Based on Route of administration, the market was studied across Injectable, Oral, and Sublingual.
  • Based on End-User, the market was studied across Hospitals and Speciality centres.
  • Based on Distribution Channel, the market was studied across Hospital pharmacy, Online pharmacy, and Retail pharmacy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Antispasmodics Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antispasmodics Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antispasmodics Drugs Market, including ACTIZA PHARMACEUTICAL, Akorn Inc., Allergan, Inc., Ambrosia Pharma, Aurobindo Pharma Limited, B JOSHI AGROCHEM PHARMA, Blue Cross Laboratories Pvt Ltd., Daiichi Sankyo Company, Limited, Dr. Reddys Laboratories Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Lannett Company, Inc., LEXICARE PHARMA PVT. LTD., Mylan N.V., Nexus Pharmaceuticals Inc., RIPCORD PHARMACEUTICALS PVT. LTD., Shanghai Fosun Pharmaceutical Co., Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, SunGen Pharma LLC, and Wellona Pharma Private Limited..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Antispasmodics Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antispasmodics Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antispasmodics Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Antispasmodics Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Antispasmodics Drugs Market?
6. What is the market share of the leading vendors in the Global Antispasmodics Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Antispasmodics Drugs Market?
Frequently Asked Questions about the Global Antispasmodics Drugs Market

What is the estimated value of the Global Antispasmodics Drugs Market?

The Global Antispasmodics Drugs Market was estimated to be valued at $11.6 Billion in 2021.

What is the growth rate of the Global Antispasmodics Drugs Market?

The growth rate of the Global Antispasmodics Drugs Market is 8.2%, with an estimated value of $18.7 Billion by 2027.

What is the forecasted size of the Global Antispasmodics Drugs Market?

The Global Antispasmodics Drugs Market is estimated to be worth $18.7 Billion by 2027.

Who are the key companies in the Global Antispasmodics Drugs Market?

Key companies in the Global Antispasmodics Drugs Market include ACTIZA PHARMACEUTICAL, Akorn Inc., Allergan, Inc., Ambrosia Pharma, Aurobindo Pharma Limited, B JOSHI AGROCHEM PHARMA, Blue Cross Laboratories Pvt Ltd., Daiichi Sankyo Company, Limited and Fresenius Kabi AG.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ACTIZA PHARMACEUTICAL
  • Allergan, Inc.
  • Aurobindo Pharma Limited
  • Fresenius Kabi AG
  • Lannett Company, Inc.
  • Mylan N.V.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High incidences of irritable bowel syndrome and adoption of inactive lifestyle
5.1.1.2. Rising healthcare expenditure and improvement in treatment
5.1.2. Restraints
5.1.2.1. Adverse effects associated with the antispasmodic drugs
5.1.3. Opportunities
5.1.3.1. Growing investment in research and development
5.1.3.2. Increasing patient awareness level and improvement in treatment
5.1.4. Challenges
5.1.4.1. Derivation of the plant-based antispasmodics
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Antispasmodics Drugs Market, by Drug type
6.1. Introduction
6.2. Dicyclomine hydrochloride
6.3. Hyoscyamine
6.4. Loperamide hydrochloride
7. Antispasmodics Drugs Market, by Route of administration
7.1. Introduction
7.2. Injectable
7.3. Oral
7.4. Sublingual
8. Antispasmodics Drugs Market, by End-User
8.1. Introduction
8.2. Hospitals
8.3. Speciality centres
9. Antispasmodics Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital pharmacy
9.3. Online pharmacy
9.4. Retail pharmacy
10. Americas Antispasmodics Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Antispasmodics Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
12. Europe, Middle East & Africa Antispasmodics Drugs Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. ACTIZA PHARMACEUTICAL
14.2. Akorn Inc.
14.3. Allergan, Inc.
14.4. Ambrosia Pharma
14.5. Aurobindo Pharma Limited
14.6. B JOSHI AGROCHEM PHARMA
14.7. Blue Cross Laboratories Pvt Ltd.
14.8. Daiichi Sankyo Company, Limited
14.9. Dr. Reddys Laboratories Ltd.
14.10. Fresenius Kabi AG
14.11. Hikma Pharmaceuticals PLC
14.12. Lannett Company, Inc.
14.13. LEXICARE PHARMA PVT. LTD.
14.14. Mylan N.V.
14.15. Nexus Pharmaceuticals Inc.
14.16. RIPCORD PHARMACEUTICALS PVT. LTD.
14.17. Shanghai Fosun Pharmaceutical Co., Ltd.
14.18. Solitaire Pharmacia Private Limited
14.19. Strides Pharma Science Limited
14.20. SunGen Pharma LLC
14.21. Wellona Pharma Private Limited.
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ANTISPASMODICS DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (USD BILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, 2019-2027 (USD BILLION)
FIGURE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 21. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD BILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2027
FIGURE 23. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, 2019-2027 (USD BILLION)
FIGURE 26. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 27. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 28. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD BILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 30. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2019-2027 (USD BILLION)
FIGURE 31. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 32. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2019-2027 (USD BILLION)
FIGURE 33. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2019-2027 (USD BILLION)
FIGURE 35. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 36. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. CANADA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. AUSTRALIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. CHINA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. INDIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. INDONESIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. JAPAN ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. MALAYSIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. PHILIPPINES ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. SINGAPORE ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. SOUTH KOREA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. TAIWAN ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. THAILAND ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. ITALY ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. NETHERLANDS ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. QATAR ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. SOUTH AFRICA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 66. GLOBAL ANTISPASMODICS DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 67. GLOBAL ANTISPASMODICS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 68. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTISPASMODICS DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ANTISPASMODICS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD BILLION)
TABLE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2019-2027 (USD BILLION)
TABLE 21. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 22. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY STATE, 2019-2027 (USD BILLION)
TABLE 23. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2019-2027 (USD BILLION)
TABLE 37. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD BILLION)
TABLE 39. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2019-2027 (USD BILLION)
TABLE 42. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 43. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY STATE, 2019-2027 (USD BILLION)
TABLE 44. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 47. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2019-2027 (USD BILLION)
TABLE 48. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2019-2027 (USD BILLION)
TABLE 50. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2019-2027 (USD BILLION)
TABLE 53. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2019-2027 (USD BILLION)
TABLE 55. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2019-2027 (USD BILLION)
TABLE 58. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 59. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2019-2027 (USD BILLION)
TABLE 60. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 62. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. CANADA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 66. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. AUSTRALIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. CHINA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 71. INDIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. INDONESIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. JAPAN ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. MALAYSIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. PHILIPPINES ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. SINGAPORE ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 77. SOUTH KOREA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. TAIWAN ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. THAILAND ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 81. FRANCE ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. GERMANY ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. ITALY ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 84. NETHERLANDS ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. QATAR ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 86. RUSSIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. SAUDI ARABIA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 88. SOUTH AFRICA ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 89. SPAIN ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. UNITED ARAB EMIRATES ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 91. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 92. GLOBAL ANTISPASMODICS DRUGS MARKET: SCORES
TABLE 93. GLOBAL ANTISPASMODICS DRUGS MARKET: BUSINESS STRATEGY
TABLE 94. GLOBAL ANTISPASMODICS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 95. GLOBAL ANTISPASMODICS DRUGS MARKET: RANKING
TABLE 96. GLOBAL ANTISPASMODICS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 97. GLOBAL ANTISPASMODICS DRUGS MARKET: MERGER & ACQUISITION
TABLE 98. GLOBAL ANTISPASMODICS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 99. GLOBAL ANTISPASMODICS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 100. GLOBAL ANTISPASMODICS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 101. GLOBAL ANTISPASMODICS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 102. GLOBAL ANTISPASMODICS DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • ACTIZA PHARMACEUTICAL
  • Akorn Inc.
  • Allergan, Inc.
  • Ambrosia Pharma
  • Aurobindo Pharma Limited
  • B JOSHI AGROCHEM PHARMA
  • Blue Cross Laboratories Pvt Ltd.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddys Laboratories Ltd.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Lannett Company, Inc.
  • LEXICARE PHARMA PVT. LTD.
  • Mylan N.V.
  • Nexus Pharmaceuticals Inc.
  • RIPCORD PHARMACEUTICALS PVT. LTD.
  • Shanghai Fosun Pharmaceutical Co., Ltd.
  • Solitaire Pharmacia Private Limited
  • Strides Pharma Science Limited
  • SunGen Pharma LLC
  • Wellona Pharma Private Limited.
Note: Product cover images may vary from those shown

Loading
LOADING...